Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen

Stenzinger, Albrecht; Tilburg, Cornelis M. van; Tabatabai, Ghazaleh; Laenger, Florian; Graf, Norbert; Griesinger, Frank; Heukamp, Lukas C.; Hummel, Michael; Klingebiel, Thomas; Hettmer, Simone; Vokuhl, Christian; Merkelbach-Bruse, Sabine; Overkamp, Friedrich; Reichardt, Peter; Scheer, Monika; Weichert, Wilko; Westphalen, C. Benedikt; Bokemeyer, Carsten; Ivanyi, Philipp; Loges, Sonja; Schirmacher, Peter; Woermann, Bernhard; Bielack, Stefan und Seufferlein, Thomas T. W. (2020): Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen. In: Pathologe, Bd. 42, Nr. 1: S. 103-115

Abstract

NTRK gene fusions are sporadic genetic alterations that can occur across tumor entities. Whereas they are quite rare in most solid tumors they are present at much higher frequencies in certain rare tumors such as infantile fibrosarcoma, congenital mesoblastic nephroma, secretory breast, or salivary gland carcinoma. NTRK gene fusions or TRK fusion proteins are considered strong oncogenic drivers. If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity. So far only larotrectinib is approved in the European Union. Both drugs have been shown to be effective and well tolerated in phase I and phase II studies. The low prevalence of TRK fusion-positive cancers poses challenges for diagnostic and clinical work-flows. On one hand, patients with NTRK gene fusions should be identified;on the other hand, epidemiological, histological, and resource-related aspects have to be taken into account. Based on these premises, we suggest a diagnostic algorithm for TRK fusion cancers and present current data on TRK inhibitors.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0172-8113
• Sprache: Deutsch